*LK's affiliation is currently Bristol-Myers Squibb and was affiliated with Roche Pharmaceuticals at the time of the study. RB's affiliation is currently Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK and was affiliated with F. Hoffmann-La Roche AG at the time of the study.
Article first published online: 26 MAR 2013
Copyright © 2012 The Obesity Society
Volume 21, Issue 2, pages 238–247, February 2013
How to Cite
Hollander, P., Lasko, B., Barnett, A. H., Bengus, M., Kanitra, L., Pi-Sunyer, F. X. and Balena, R. (2013), Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity, 21: 238–247. doi: 10.1002/oby.20042
Disclosures: The T-emerge 7 study was funded by F. Hoffmann-La Roche Ltd. Priscilla Hollander had membership on advisory panels and standing committees for NovoNordisk, Merck, Pfizer, Orexigen, and Roche and received honoraria or consulting fees from NovoNordisk, Merck, Pfizer, Orexigen, and Roche. Anthony Barnett received honoraria or consulting fees from Roche, MSD, Bristol-Myers Squibb/Astra Zeneca, Boehringer-Ingelheim, Lilly, NovoNordisk, Sanofi-Aventis, and Novartis. Ben Lasko declared no conflict of interest. Xavier Pi-Sunyer had membership on advisory panels, standing committees, or board of directors for Amylin, NovoNordisk, Weight Watchers, McNeil Nutritionals, Lilly, and Vivus and received grant/research support from Arena, Astra Zeneca, Merck, Schering-Plough, Orexigen, and Vivus. Monica Bengus is an employee of F. Hoffmann-La Roche AG. Linda Kanitra's affiliation is currently Bristol-Myers Squibb and was affiliated with Roche Pharmaceuticals at the time of the study. Raffaella Balena is an employee of Eli Lilly and Company Ltd and was affiliated with F. Hoffmann-La Roche AG at the time of the study.
Funding agencies: The T-emerge 7 study was funded by F. Hoffmann-La Roche Ltd.
- Issue published online: 26 MAR 2013
- Article first published online: 26 MAR 2013
- Accepted manuscript online: 18 SEP 2012 02:55PM EST
- Manuscript Received: 19 OCT 2012
- Manuscript Accepted: 7 JUL 2012
- F Hoffmann-La Roche Ltd
Therapies that lower blood glucose and provide weight loss may provide meaningful benefits for obese patients with type 2 diabetes mellitus (T2DM). This study assessed the efficacy of taspoglutide compared with placebo on glycemic control and weight in obese patients with T2DM inadequately controlled with metformin monotherapy.
Design and Methods:
In a 24-week, randomized, double-blind, placebo-controlled, multicenter trial, obese adults with T2DM were randomized (1:1) to weekly subcutaneous taspoglutide 20 mg (10 mg for first 4 weeks) (n = 154) or placebo (n = 151) for 24 weeks. Efficacy measures included hemoglobin A1c (HbA1c) levels, body weight, percentage of patients achieving HbA1c ≤6.5 and ≤7.0%, and fasting plasma glucose (FPG). Adverse events (AEs) were assessed.
Mean baseline HbA1c was 7.55% and mean baseline BMI was 36.7 kg/m2. HbA1c reductions from baseline were significantly greater with taspoglutide than placebo (least square mean [LSMean], −0.81% vs. −0.09%; P < 0.0001). Weight loss at week 24 was significantly greater with taspoglutide than placebo (LSMean, −3.16 vs. −1.85 kg; P < 0.01). In the taspoglutide and placebo groups, target HbA1c levels (≤6.5%) were achieved by 49 and 16% of patients, respectively, while 72 and 36% achieved HbA1c levels ≤7%. Decreases in FPG were significantly greater with taspoglutide than placebo (−23.59 vs. 0.09 mg/dl; P < 0.0001). Nausea and vomiting were the most common AEs associated with taspoglutide, but tended to be transient and generally mild or moderate.
In obese patients with T2DM, once-weekly taspoglutide provided the combined benefits of glycemic control and weight loss.